TrialJournal of the Pediatric Infectious Diseases Society2021

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

Paul Krogstad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.